Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
Abdul Rahman
AR
El Kinge
Hassan A
HA
Hatoum
Rami A
RA
Mahfouz
Zaher K
ZK
Otrock
Elias
E
Jabbour
Hagop
H
Kantarjian
Ali
A
Bazarbachi
D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab